Member Info for Spencer1983

I think Debt funding is fast approaching. SO4 Australia SP finished 6% up and haven’t seen it finish that high before since I’ve been a shareholder over the last 5 months. It points that the debt funding RNS could be tomorrow.

https://www.theguardian.com/science/2020/jul/16/coronavirus-vaccine-oxford-team-volunteers-lab-controlled-human-challenge-trial

There was an RNS today from Cathal’s other company Amryt Pharma advising that they’re shortly going to be on the NASDAQ stockmarket. If Cathal can’t sell Imutex at the good price then could his other company be the one Imutex is spun off with to enable it to be on NASDAQ as well.

Deepjoy will be back. He loves it and can’t stay away........!

Below is what I take from Cathal’s IGTV interview that was posted into Twitter this morning by HVIVO:

Fund managers refer to HVIVO as a treasure trove, a gold mine.

Spectacular pick up on antibody testing and started doing tests in Ireland.

COVID-19 challenge study model taking shape and in discussions with 12 pharmaceutical companies. Expect to sign 5 or 6 Contracts by the end of the year each between $8 - $10 million.

Even if COVID-19 disappears tomorrow then we will still have a very successful business.

In the coming month hoping to do another Venn Contract with another top 3 pharmaceutical company.

2 Assets in Imutex (Flu-v and AGS-v). So my question is where does that leave Biopharma (or what ever it’s called, is it going to be another asset that could be sold?).

ORPH is always for sale.

Hope to have the market cap back up to £100 million within the next few weeks.

ORPH will be profitable in H2 later this year.

If the company achieves half of what it’s expecting to do then in December it will be unrecognisable compared to where it currently is today.

Cathal said last week that they were overwhelmed with antibody test enquires and it was going just how they hoped and imagined it would.

Don’t believe we will get an RNS when Acacia are out because their last holdings RNS notes they were under 3%. Once notified you’re under 3% then you don’t have to notify the market again once out.

Anyone who has done their research will know that Open Orphan doesn’t rely on COVID-19. Cathal Friel has said non COVID revenue this year is £30 million and the assets we own are worth £60 million therefore even if COVID vanished tomorrow then the company would be worth £120 - £150 million once profitable, which it will in H2 this year. Current market cap circa £70 million therefore nearly the value of ORPH’s assets alone.

Been hearing a lot of stuff on Twitter about a second wave not coming therefore COVID plays are dead. It's simply untrue, and I want to explain why these companies are not dead if there's no second wave. I work for an F1 team in the UK. We have a policy for the next 12/18 months where we must take regular COVID tests to enter the workplace to ensure our factory doesn't shutdown again (otherwise no upgrades will get to the cars). This means that, for my (small) team alone, we will need 400 tests/week. Similar policies are in place elsewhere, meaning the F1 workforce in the UK will need around 4000 tests/week. This doesn't include officials for races, purely for engineers. What am I getting at here? These are measures to PREVENT spikes in the virus, even if none of the employees have got it. The same will be happening all over the UK and across the world. Businesses and the economy overall cannot survive a second wave, therefore preventing it is of the highest priority. Thus, the threat of a second wave alone is enough to ensure COVID tests will be sold for a while to come.

I think ORPH’s decision to concentrate on big companies is a very shrewd move.

Above message taken from Twitter.

Cathal said in a couple of interviews ago that he believes ORPH could become a company that’s worth many hundreds of million pounds. How many is “many”? Well it’s more than a few and more than several for starters. Even if we say “many” in this scenario is just 5, that’s a 500 million pound company and it’s current market cap is £87 million (off the top of my head without looking. That’s then over a 5 bagger.

“Open Orphan is no longer worth just £100 million, it is now worth multiples of the current share price and has a long way to go yet.” Cathal’s words from this evenings presentation.

Remember somebody (company) bought over £500K worth of shares at the start of the week. Yes somebody spent over half a million pounds! That’s the biggest trade I’ve seen for ORPH. Some will buy and sell for a few % gain but the most £ will be made in the long run.

You know you’re in a good company when derampers are around trying to get a lower share price entry or worried that their investment in another stock is under threat. It’s obvious that some people don’t do any research as for example ORPH is looking to do antibody lab tests not finger prick home kit tests. I have 110,00 shares at an average of 6.01p and not sold a single share. This share price is going a lot higher and anybody who has done the slightest bit of research will know that. Best of luck to all other genuine shareholders only.

Looks like some people sold out this morning looking for a quick entry at a lower SP. The subscription was 5 times oversubscribed by institutions. A few bullish long term holders have now turned negative, which is a shame. From raising just £12 million the pipeline of potential revenue has now increased from £81 million to £160 million and that doesn’t include the £84 million for COVID-19 challenge study models as the model still needs approving. Many blue chip companies who before wouldn’t give Cathal a meeting beforehand are now piling in and most of these shares will be in sticky hands. Looking forward to seeing who the new institutional shareholders are. Good luck for all other genuine investors, by the sounds of it we are going to be very handsomely rewarded.

It was the 8 challenge study models that cost £30 million.

People who have done a bit of research will know when the clinic is going to open and the reasons why it had closed because Cathal answered this question a few weeks ago. This just goes to show how clueless some people are when the answer is already out there. If somebody is going to try and de-ramp then at least come up with something that’s debatable. I think that’s a fair view don’t you.

Why have a couple of people mentioned Cathal selling the company for £100 million. That was his target before the pandemic. Anywhere between £300 million to £600 million is my target now.

JohnHenry being positive. What’s with the change of tune?? Guess they must have bought in. I just ignore the “noise” and only look out for genuine fellow shareholders who post useful information. Have no time what so ever for people who are hot on a stock one day and cold on it another depending on their position. I know it happens but it’s very muggy and unethical.

Anybody who says we desperately need news either hasn’t researched the company properly therefore is worried about their investment or they are trader and wanting their 10%. Everybody else is just relaxed and waiting for the story to be told as they know what’s coming.

He said if Flu-v came off then the money received would be distributed among shareholders.